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Abstract
Background: In Southeast Asia, HIV-infected patients frequently die during TB treatment. Many
physicians are reluctant to treat HIV-infected TB patients with anti-retroviral therapy (ART) and
have questions about the added value of opportunistic infection prophylaxis to ART, the optimum
ART regimen, and the benefit of initiating ART early during TB treatment.
Methods:  We conducted a multi-center observational study of HIV-infected patients newly
diagnosed with TB in Thailand. Clinical data was collected from the beginning to the end of TB
treatment. We conducted multivariable proportional hazards analysis to identify factors associated
with death.
Results: Of 667 HIV-infected TB patients enrolled, 450 (68%) were smear and/or culture positive.
Death during TB treatment occurred in 112 (17%). In proportional hazards analysis, factors
strongly associated with reduced risk of death were ART use (Hazard Ratio [HR] 0.16; 95%
confidence interval [CI] 0.07–0.36), fluconazole use (HR 0.34; CI 0.18–0.64), and co-trimoxazole
use (HR 0.41; CI 0.20–0.83). Among 126 patients that initiated ART after TB diagnosis, the risk of
death increased the longer that ART was delayed during TB treatment. Efavirenz- and nevirapine-
containing ART regimens were associated with similar rates of adverse events and death.
Conclusion:  Among HIV-infected patients living in Thailand, the single most important
determinant of survival during TB treatment was use of ART. Controlled clinical trials are needed
to confirm our findings that early ART initiation improves survival and that the choice of non-
nucleoside reverse transcriptase inhibitor does not.
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Background
Globally, an estimated nine million new cases of TB occur
annually, resulting in almost two million deaths [1]. The
HIV pandemic has increased TB incidence and mortality,
because HIV greatly increases the risk of developing TB
disease and complicates diagnosis and treatment of TB
[2]. In Southeast Asia, mortality from HIV-associated TB is
particularly high; after diagnosis of TB, up to 50% of HIV-
infected patients may die during TB treatment [3,4]. Pro-
spective epidemiologic studies from resource rich coun-
tries and Thailand have shown that anti-retroviral therapy
(ART) greatly reduces mortality during TB treatment [5-9].
In patients not prescribed ART, co-trimoxazole has been
shown to reduce mortality [10,11]. The World Health
Organization (WHO) currently recommends that all HIV-
infected TB patients receive co-trimoxazole and that
patients with clinical evidence of AIDS or CD4+ T-lym-
phocyte counts (CD4) <350 cells/μL initiate ART during
TB treatment [2]. Despite international recommendations
and the proven benefit of ART, physicians remain reluc-
tant to prescribe ART to HIV-infected TB patients, because
of concerns about overlapping toxicity, drug-drug interac-
tions, pill burden, and immune reconstitution inflamma-
tory syndrome (IRIS) [12]. Major research questions also
remain unanswered, including the optimum time to initi-
ate ART, the optimum ART regimen in HIV-infected TB
patients, and the added value to ART of co-trimoxazole
and other opportunistic infection prophylaxis medica-
tions in reducing mortality during TB treatment [13].
Clinical trials are currently in progress to help answer
some of these questions [14].
Thailand has been greatly affected by the TB/HIV syn-
demic: TB develops annually in 91,000 persons, 15–20%
of whom are HIV-infected [1,15,16]. While awaiting the
results of clinical trials in other countries, we sought to
evaluate factors associated with mortality in a prospective,
multi-center, observational study of HIV-infected patients
treated for TB in Thailand. Our specific purpose was to
identify and quantify the relative benefit of biomedical
interventions associated with survival during TB treat-
ment, to evaluate the optimum time to initiate ART, and
to evaluate adverse events and survival associated with dif-
ferent ART regimens.
Methods
Setting
Patients were recruited from 32 public TB treatment facil-
ities from May 2005 through September 2006. The catch-
ment area included the entire provinces of Ubon
Ratchathani and Phuket, 10 districts in Bangkok, and the
national infectious diseases hospital in Nonthaburi prov-
ince. All facilities were government-supported hospitals
that had both outpatient TB clinics and inpatient treat-
ment centers from which patients could be enrolled.
Excluding the national hospital, which has no base popu-
lation, the population covered was 3.1 million persons. In
all facilities, TB patients are routinely registered and
treated in a specialized clinic; physicians in these facilities
are instructed, but not required, to use national guidelines
for TB diagnosis and treatment. As part of a multi-site
demonstration project known as the Thailand TB Active
Surveillance Network, public health staff in these facilities
recorded standardized data about all patients diagnosed
with TB, and clinical staff were encouraged to send spu-
tum specimens for mycobacterial culture and to provide
HIV counseling and testing [17].
Enrollment
Patients who were registered in the Thailand TB Active
Surveillance Network and who were documented to be
HIV-infected were screened for eligibility by study staff.
HIV-infected TB patients were eligible for the study if they
had been receiving anti-TB treatment for less than four
weeks at the time of enrollment and were greater than 17
years old, not known to be pregnant, and not incarcer-
ated. Additionally, patients had to report that they
planned to remain in the study sites' TB treatment pro-
gram for the duration of TB treatment. Eligible patients
were informed about the study and, if they agreed to par-
ticipate, were consented for participation.
Study evaluations
At enrollment, trained clinical nurses interviewed patients
using a standardized questionnaire that asked about a
large number of demographic, knowledge, behavioral,
and medical characteristics. Clinic physicians recorded
physical examination findings on study forms. Blood and
sputum specimens were collected for testing. Patients ini-
tiated treatment for TB, HIV, and other diseases according
to physician preference; no efforts were made to modify
routine clinical practice.
After two months of initial TB treatment and at the end of
TB treatment, patients were interviewed and examined
again. Study staff abstracted medical records of patients
who received care between study visits. Patients were not
followed after TB treatment ended. To determine if
patients died after defaulting, we linked patients who
defaulted during TB treatment to the Thai government's
vital status registry, a system known to be relatively com-
plete [18]. Patients who died within three months of
defaulting were classified as deaths during study follow-
up. In total, 11 patients who were originally classified as
defaulters were later re-classified as deaths.
Laboratory studies
Patients diagnosed with pulmonary TB provided sputum
specimens for smear microscopy. Unprocessed sputum
was analyzed in TB clinics using the Ziehl-Neelsen acid-BMC Infectious Diseases 2009, 9:42 http://www.biomedcentral.com/1471-2334/9/42
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fast stain method. Similarly, as part of our Active Surveil-
lance Network program, we encouraged, but did not
require, that at least one sputum specimen be sent for
mycobacterial culture, identification, and drug-suscepti-
bility testing. Mycobacterial culture was performed at one
laboratory in each province using both Lowenstein-Jensen
and mycobacterial growth indicator tube (MGIT) media,
according to standard methods [19]. Identification and
first-line drug-susceptibility testing was performed at ref-
erence laboratories in Bangkok; indirect drug susceptibil-
ity testing using the proportion method was performed on
BACTEC MGIT 960 [20].
Blood specimens collected at enrollment underwent a
complete blood count, testing for hepatitis B surface anti-
gen (HBsAg) and hepatitis C antibody (anti-HCV), enu-
meration of CD4 using a flow cytometer, and
measurement of serum albumin, creatinine, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and total bilirubin. Plasma specimens from selected
patients were tested for HIV RNA using polymerase chain
reaction (Amplicor HIV Monitor Test, version 1.5, Roche
Molecular Systems, Branchburg, NJ, USA).
Definitions
Patients were defined as having bacteriologic-confirmed
TB if at least one specimen collected at any time before or
during treatment was positive for acid-fast bacilli and/or
culture-positive for Mycobacterium tuberculosis (MTB).
Patients with specimens that grew non-tuberculous myco-
bacteria and not MTB were considered not to have TB and
excluded from all analyses.
We developed composite variables to measure factors ini-
tially hypothesized to be associated with death during TB
treatment. Patients were considered to have a delay in
seeking TB care if they reported: (a) having a cough lasting
greater than one month before TB diagnosis; or (b) having
other symptoms that lasted longer than 14 days and self-
assessed these symptoms as being severe. Patients were
considered to have a delay in HIV diagnosis if their CD4
count at the time of HIV diagnosis was <200 cells/μL; we
used standard assumptions to estimate CD4 count at the
time of HIV diagnosis for patients with a pre-existing HIV
diagnosis, no CD4 count recorded at the time of HIV diag-
nosis, and no history of ART treatment [21-23].
Except for peripheral lymphatic TB, patients were consid-
ered to have severe TB disease if they had extra-pulmonary
TB or had pulmonary TB with any of the following char-
acteristics: self-reported weight loss, hemoptysis, dyspnea,
or chest x-ray findings of a cavity or infiltrates involving
>1/3 of either lung. Patients were considered to have
severe HIV disease if their CD4 count at study enrollment
was <200 cells/μL. Patients were considered to be receiv-
ing inadequate TB treatment if the anti-TB regimen pre-
scribed was not consistent with international recommend
ations or was inadequate because of documented MTB
drug resistance. Patients were considered to have elevated
liver-associated enzymes if they had an AST ≥ 120 mEq/L,
ALT ≥ 165 mEq/L, or total bilirubin >2 mg/dL.
We defined IRIS as worsening fever, cough, shortness of
breath, lymphadenopathy, radiographic abnormalities, or
extra-pulmonary TB lesions in a patient that was being
treated with ART, had initially improved clinically after
initiating TB treatment, and had no other diagnosis that
could explain their new symptoms [24,25].
Analytical methods
We calculated medians and proportions to describe char-
acteristics of our study population. To determine risk fac-
tors for death, we restricted our analysis to patients who
were never previously treated with TB and who were
known to be either alive or dead at the end of TB treat-
ment. We calculated time from TB treatment initiation to
death or to the end of TB treatment. We created an
"unknown" category for any categorical covariate with
missing data for ≥10 observations. After confirming that
the proportional hazards assumption was met, we con-
structed a Cox proportional hazards model that included
factors hypothesized to be associated with death and fac-
tors that were consistently associated with death at p ≤
0.20 in bivariate analysis of all patients and of bacterio-
logic-confirmed patients. For this analysis, we excluded
patients who started co-trimoxazole, fluconazole and ART
before TB treatment initiation, because we could not
account for whether they had been continuously taking
these medicines. Two-way interaction terms were gener-
ated as products of covariates and entered in the models;
none were retained in the final models. We also con-
structed Kaplan-Meier survival curves adjusted for factors
associated with mortality to evaluate the association
between ART and time to death.
To measure the association between timing of ART initia-
tion and mortality during TB treatment, we restricted our
proportional hazards analysis to patients that initiated
ART during TB treatment. Because our sample size for this
analysis was small, we only adjusted for selected factors,
such as TB and HIV disease severity. We excluded 10
patients who were treated with a non-standard or ineffec-
tive anti-TB drug regimen from this analysis, because the
small number made our model unstable.
To determine whether the choice of ART regimen was
associated with different TB treatment outcomes, we ana-
lyzed the likelihood of treatment success (cured or com-
pleted TB outcomes) vs. a composite end point of death
and default or death only for patients that received nevi-BMC Infectious Diseases 2009, 9:42 http://www.biomedcentral.com/1471-2334/9/42
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rapine-containing regimens versus those that received efa-
virenz-containing regimens.
Ethical review
This study was approved by the ethical review committees
at the U.S. Centers for Disease Control and Prevention,
the Thailand Ministry of Public Health, and the Bangkok
Metropolitan Administration.
Results
Enrollment
From May 2005 – September 2006, 5,851 TB patients
were registered for treatment in the participating sites, and
1,796 (31%) were known to be HIV-infected. [Figure 1]
Among the 700 patients not eligible for the study, the
most common reason for ineligibility was patients taking
anti-TB treatment for at least four weeks before presenting
to a participating facility (n = 469). Of the 1,096 eligible
patients, 849 (78%) were enrolled. We later excluded
from analysis patients who reported previously being
treated for TB or subsequently were diagnosed as not hav-
ing TB. Of the 80 patients excluded because of a change in
diagnosis, 70 (87%) had non-tuberculous mycobacteria
diagnosed. The remaining 667 HIV-infected, new TB
patients were eligible for analysis.
Characteristics of cases
Most patients were men with a median age of 34 years
(range, 18–77).[Additional file 1, Table 1] Pulmonary TB
was diagnosed in 387 (58%), extra-pulmonary TB in 206
(31%), and both pulmonary and extra-pulmonary TB in
74 (11%). Bacteriologic-confirmation of TB was docu-
mented in 450 (68%), 352 (78%) of whom had culture-
confirmed MTB. Resistance to isoniazid and rifampin (or
multi-drug resistant [MDR] TB) was diagnosed in 16
(2%). Over 80% had CD4 < 200 cells/μL; among 12
patients with CD4 > 200 cells/μL who had HIV RNA viral
load test performed, 7 (58%) had greater than 100,000
copies/mL. Serologic testing for viral hepatitis identified
54 (8%) positive for HBsAg and 192 (30%) for anti-HCV.
At the beginning of TB treatment, 110 (17%) had elevated
liver-associated enzymes.
TB and HIV care and treatment
A health care worker directly observed TB treatment
(DOT) for 191 (29%) patients. Of all 667 patients, 430
(65%) were cured or completed TB treatment; 112 (17%)
died during TB treatment.
Rates of opportunistic infection prophylaxis use were
high: before TB treatment, 215 (32%) were taking co-tri-
moxazole and 117 (18%) fluconazole; during TB treat-
ment, an additional 338 (51%) began using co-
trimoxazole and 259 (39%) fluconazole.
ART was prescribed to 273 (41%) patients during TB treat-
ment, 73 (27%) of whom were receiving ART before TB
diagnosis. In the 200 patients that initiated ART at the
beginning or during TB treatment, the median time
between TB diagnosis and ART initiation was 62 days
(range, 0–386 days). Among all 273 patients receiving
ART, 113 (41%) took an efavirenz-containing regimen,
and 147 (54%) took a nevirapine-containing regimen. Of
the 147 patients who took nevirapine, 5 (3%) switched to
efavirenz during TB treatment; of these, two switched reg-
imens at 29 and 242 days into TB treatment, respectively,
while the exact date of medication change was not
recorded for other three patients. For later analyses, all five
patients were classified as taking a nevirapine-containing
regimen. The remainder took other ART regimens (n = 3)
or had incomplete data about the drugs or dates involving
their ART regimen (n = 10).
Risk factors for death during TB treatment
Unadjusted mortality rates, stratified by microbiologic
status and various patient characteristics, are shown in
Additional file 1, Table 2. In proportional hazards analy-
sis, co-trimoxazole, fluconazole, and ART use were associ-
ated with a lower risk of death in all TB patients. In the
subset of bacteriologic-confirmed patients, fluconazole
and ART use remained strong protective factors.[Addi-
tional file 1, Table 3] In the analyses of bacteriologic-con-
firmed patients, DOT for TB was associated with a lower
risk of death; while hospitalization at enrollment, having
lower CD4, and a missing albumin level were associated
with higher risk of death. The survival probability for all
patients and bacteriologic-confirmed patients is shown in
Figure 2.
Timing of ART
In a proportional hazards model adjusted for TB disease
severity and CD4, the risk of death increased the longer
ART was delayed. [Figure 3] The association between tim-
ing of ART and death was only statistically significant,
however, when comparing those that initiated ART within
the first 120 days of TB treatment to those who started
later: among bacteriologic-confirmed cases, hazard ratio
[HR] 9.0, 95% confidence interval [CI] 1.1–73.0.
Adverse events and ART choice
Adverse events occurred with similar frequency in ART
treated and untreated patients.[Additional file 1, Table 4]
Rash was reported more frequently in ART-untreated
patients (18%) than in patients receiving either nevirap-
ine- (12%) or efavirenz-containing (11%) regimens, but
this was not statistically significant (p-value = 0.09). Four-
teen patients (2% of all; 5% of those taking ART) met our
case definition of IRIS; IRIS occurred in 7 (5%) patients
taking nevirapine regimens and 7 (6%) taking efavirenz
regimens.BMC Infectious Diseases 2009, 9:42 http://www.biomedcentral.com/1471-2334/9/42
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Adjusting for factors associated with TB treatment success,
we found that efavirenz- or nevirapine-containing ART
was associated with a decreased risk of death or of death
and default, compared with no ART, and that there was no
significant difference in outcomes when comparing nevi-
rapine- vs. efavirenz-containing regimens.[Additional file
1, Table 5]
Discussion
In this prospective, multi-center observational study of
HIV-infected TB patients, we found that patients who took
ART had one-fifth the risk of dying than those who did not
take ART, and that the risk of dying was further reduced
with early ART initiation and concomitant use of flucona-
zole. The choice of non-nucleoside reverse transcriptase
inhibitor (NNRTI) in the ART regimen did not alter the
risk of adverse events or death.
Our study adds to previous observational data about the
benefit of ART on survival during TB treatment, because it
collected data prospectively, enrolled a diverse group of
patients from multiple centers, and adjusted for a large
number of factors associated with severity of illness, med-
ication use, and treatment outcome. In addition to con-
firming the benefits of ART, we also found an
independent survival benefit to using fluconazole proph-
ylaxis during TB treatment, likely because fungal oppor-
tunistic infections are a major problem in Southeast Asia
[26]. Because over 80% of patients in this study met
immunological criteria for AIDS, we expected that co-tri-
moxazole, which is internationally recommended as
prophylaxis against Pneumocystis jirovecii pneumonia, tox-
oplasmosis, and other infections, would increase survival,
but the point estimate was only statistically significant in
the all patients analysis, not the subset of bacteriologic-
confirmed patients [27]. In Africa, some of co-trimoxa-
zole's benefit has been ascribed to reducing malaria
deaths [28]. It is possible that the magnitude of benefit
from co-trimoxazole is not as great among HIV-infected
TB patients that are receiving ART and living in settings
with less malaria, such as Thailand. It is also possible that
patients did not initiate co-trimoxazole early enough to
reduce HIV-associated deaths that occurred early during
TB treatment, that antimicrobial resistance mitigated the
benefit of co-trimoxazole, or that our study was under-
powered to show a strong beneficial effect. Further pro-
spective studies would help define the added value of co-
trimoxazole and fluconazole to ART in reducing mortality
during TB treatment.
International guidelines recommend that HIV-infected
persons initiate treatment with nevirapine, zidovudine,
and lamivudine; because rifampin can alter drug levels of
nevirapine, guidelines recommend that efavirenz replace
nevirapine in patients receiving rifampin [29]. The high
cost of switching from nevirapine to efavirenz has led
some physicians in resource-limited settings to continue
using nevirapine in HIV-infected TB patients, a decision
backed by a pharmacokinetic study in Thailand that
showed good HIV and TB treatment outcomes in patients
receiving nevirapine and rifampin at the same time [30].
Our study is unique, because it compared the frequency of
adverse events and TB treatment outcomes in patients
receiving either efavirenz or nevirapine containing regi-
mens during TB treatment. In our study, adverse events
and successful TB outcome occurred with similar fre-
quency in both groups. Although nevirapine is frequently
associated with rash, we found that rash was infrequent in
both ART groups; in fact, patients not treated with ART
reported rash more frequently, likely because of progres-
sive cutaneous disease associated with declining CD4
count [31]. We did not, however, serially evaluate HIV
RNA viral load or CD4 to assess the benefits of nevirapine
vs. efavirenz in achieving HIV treatment success. Current
international guidelines also recommend that patients
with advanced immune-suppression begin ART within
two weeks to two months of beginning TB treatment [2].
Although our study supports this recommendation, we
were only able to demonstrate statistical significance for
ART initiated within four months of TB treatment. The
non-randomised design, relatively small sample size, lack
of pharmacokinetic data, and lack of detailed efficacy and
Enrollment of HIV-infected tuberculosis patients in study Figure 1
Enrollment of HIV-infected tuberculosis patients in 
study.
HIV-infected TB 
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TB patients seen at participating 
sites, n=5,851 BMC Infectious Diseases 2009, 9:42 http://www.biomedcentral.com/1471-2334/9/42
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safety endpoints make our data about choice of NNRTI
and timing of ART initiation hypothesis generating. Stud-
ies with larger sample sizes, controlled designs, and more
extensive clinical monitoring data are needed to further
assess the appropriateness of using nevirapine and
rifampin concomitantly and to define the best time to ini-
tiate ART.
Our study is subject to important limitations. First, even
though our study was derived from a diverse population
base, some patients refused HIV testing, and our analysis
was limited to a subset of HIV-infected TB patients, due to
strict eligibility criteria and specific research questions. It
is possible that patients included in our analysis differ in
important ways from patients not included, such as those
previously treated for TB, and that separate studies of
these populations are needed. Second, patients only
underwent three study visits, even though treatment was
for a minimum of six months, and patients had limited
laboratory monitoring. It is possible, therefore, that ascer-
tainment of adverse events, e.g., hepatitis, was incom-
plete. Third, because this was an observational study,
patients who developed adverse events underwent evalu-
ation by their individual physicians. We do not have suf-
ficient information to assign a specific toxicity grade to
each adverse event.
Conclusion
In conclusion, our study highlights important issues
about the timing and choice of ART and the added benefit
Cumulative survival probability for HIV-infected TB patients that received or did not receive ART Figure 2
Cumulative survival probability for HIV-infected TB patients that received or did not receive ART. TB, tubercu-
losis; HIV, human immunodeficiency virus; ART, anti-retroviral therapy. Kaplan-Meier survival curves were adjusted for covari-
ates associated with mortality.
            1. All TB patients                                 2. Bacteriological-confirmed TB BMC Infectious Diseases 2009, 9:42 http://www.biomedcentral.com/1471-2334/9/42
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Log hazard ratio for mortality among all HIV-infected tuberculosis patients (n = 174) and patients who had bacteriologic-con- firmed tuberculosis (n = 127) and initiated ART during anti-tuberculosis treatment Figure 3
Log hazard ratio for mortality among all HIV-infected tuberculosis patients (n = 174) and patients who had 
bacteriologic-confirmed tuberculosis (n = 127) and initiated ART during anti-tuberculosis treatment. TB, tuber-
culosis, HIV, human immunodeficiency virus; ART, anti-retroviral therapy; HR, hazard ratio; CI, confidence interval; only those 
who received a TB regimen of known efficacy and started ART at the beginning or during TB treatment were included; the 
analyses were adjusted for TB disease severity and CD4. *Among all TB patients. †Among bacteriologic-confirmed TB patients.
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of opportunistic infection prophylaxis in patients receiv-
ing ART and TB treatment. Unfortunately, ART remains
underused in HIV-infected TB patients in Thailand and
other resource-limited settings. Reducing mortality in this
population will require intensive collaboration between
HIV and TB programs to insure prompt HIV testing and
initiation of life-saving treatment.
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